Fat-Filled Droplets Power the Deadliest Childhood Brain Tumours

Medulloblastoma is the most common malignant brain tumour in children, and despite decades of progress in surgery, chemotherapy and radiotherapy, its most aggressive forms remain stubbornly lethal. Now, a team of researchers led by Kian Cotton and Maria Victoria Niklison-Chirou at the University of Bath, working with collaborators in Italy, the United States, Spain and the United Kingdom, has uncovered an unexpected vulnerability in the hardest-to-treat subgroups of the disease: tiny globules of fat inside tumour cells that appear to serve as a critical energy reservoir. The study, published in Cell Death Discovery, suggests that these structures, known as lipid droplets, are not merely passive storage depots but active participants in the metabolic machinery that keeps high-risk medulloblastoma cells alive.

The research focused on Group 3 and Group 4 medulloblastoma, molecular subgroups that are driven in part by the potent growth gene MYC and that account for a large share of poor outcomes in patients. These tumours, along with aggressive sonic hedgehog-driven cases, often resist current therapies, and the gold standard treatment regimen of surgical resection combined with intensive chemotherapy and radiotherapy carries severe developmental side effects for young patients. That combination of poor survival and harsh treatment has made the search for new therapeutic angles in these subgroups a pressing clinical priority, and metabolism has emerged as one of the most promising frontiers.

Metabolic reprogramming, the process by which cancer cells rewire their biochemical pathways to fuel relentless growth, is now recognised as a hallmark of tumour progression. One of its most striking features is upregulated lipid metabolism, which allows cancer cells to survive when nutrients become scarce. Rapidly dividing tumours must manufacture or import large quantities of fatty molecules to build new membranes, generate signalling intermediates and produce energy. But handling excess fat is dangerous business: free fatty acids accumulating inside a cell can reach toxic levels, damaging membranes and triggering cell death. Cells therefore need a way to buffer this lipotoxicity, and that is precisely where lipid droplets come in.

Lipid droplets are dynamic intracellular organelles consisting of a neutral lipid core, largely composed of triglycerides and cholesterol esters, wrapped in a phospholipid monolayer studded with proteins. Far from being inert blobs, they protect cells against lipotoxicity by sequestering potentially harmful lipids in a safe, retrievable form, and they can be broken down on demand to release fatty acids for energy production. Yet, as the authors note, their involvement in high-risk medulloblastoma subgroups had remained poorly understood. The new study set out to close that gap using a combination of transcriptomics, the systematic measurement of gene activity, and lipidomics, the comprehensive profiling of the lipid species present in cells, across a panel of medulloblastoma cell lines representing the disease’s molecular diversity.

The results were striking. High-risk medulloblastoma cells, particularly those from Group 3 and Group 4, carried increased numbers of lipid droplets compared with their lower-risk counterparts. Alongside this physical abundance of fat storage, the researchers observed elevated expression of PLIN2, a protein that coats the surface of lipid droplets and is widely used as a molecular marker of their presence. Perilipin 2, as PLIN2 is formally known, helps stabilise droplets and regulates access of fat-breaking enzymes to the stored lipids, so its upregulation indicates not just more droplets but a coordinated cellular programme of lipid storage.

Crucially, the team did not rely on cell lines alone. In an analysis of human tissue microarrays, collections of tiny tumour samples from many patients arranged on a single slide for parallel examination, the increased PLIN2 expression was confirmed in actual patient tissue. This consistency between laboratory models and clinical specimens strengthens the case that lipid droplet accumulation is a genuine feature of high-risk medulloblastoma rather than an artefact of growing tumour cells in a dish, and it raises the possibility that PLIN2 could serve as a prognostic marker, helping clinicians identify the most dangerous tumours.

Digging into the mechanism, the researchers found that the excess droplets arise from an enhanced flux of lipids into the cell from three directions at once: de novo lipogenesis, the internal manufacture of fatty acids from scratch, typically from surplus glucose; cholesterol biosynthesis, the cell’s own production of sterol building blocks; and lipid uptake, the import of fatty molecules from the surrounding environment. When the team delivered various lipids to the cells from outside, they observed an altered maturation of lipid droplets in the high-risk cells, suggesting that these tumour cells handle incoming fat differently from less aggressive ones, processing and packaging it in a distinctive way that supports their survival.

The study’s title points to the functional payoff of all this lipid handling: cholesterol esters stored within lipid droplets play a key role in energy production in Group 3 and Group 4 medulloblastoma cells. In other words, the droplets are not just a waste-disposal system for excess fat; they function as fuel tanks. Stored cholesterol esters can be mobilised and channelled into the cell’s energy-generating pathways, providing a metabolic lifeline that may be especially valuable in the nutrient-deprived conditions that tumours frequently encounter deep within the brain. This reframes lipid droplets as an active component of the cancer cell’s energy economy in these aggressive subgroups.

Altogether, the authors conclude that high-risk Group 3 and Group 4 medulloblastoma cells use lipid droplets in response to their own excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker. The therapeutic logic is appealing: if tumour cells depend on droplet-mediated lipid storage and mobilisation to survive, then drugs that block droplet formation, destabilise PLIN2-coated droplets or prevent the release of stored lipids could selectively starve the cancer cells while sparing healthy tissue. Such an approach could complement or reduce the need for the aggressive chemo- and radiotherapy that currently causes severe developmental side effects in children. The work was funded by a grant from the Little Princess Trust, an Academy of Medical Sciences Springboard award and a startup grant from the University of Bath. While the findings are at an early stage and will need to be validated in further preclinical studies before any clinical application, they add medulloblastoma to a growing list of cancers whose vulnerabilities lie not in their genes alone but in the fat they store, and they offer a concrete molecular handle, PLIN2 and the cholesterol ester-filled droplets it marks, on which the next generation of therapies might be built.

Subject of Research: Lipid droplet metabolism and cholesterol ester storage in high-risk medulloblastoma cells

Article Title: Cholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells

Article References: Cotton, K., Edwards, C., Papapanagiotou, O., Smirnov, A., Candi, E., Imperiali, B., Agostini, M., Delaidelli, A., López-Duarte, I., Sherin, P., Kuimova, M., Craig, T. J., & Niklison-Chirou, M. V. (2026). Cholesterol esters in lipid droplets play a key role in the energy production of G3/G4 medulloblastoma cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03371-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03371-w

Keywords: medulloblastoma, lipid droplets, cholesterol esters, PLIN2, cancer metabolism, paediatric brain tumour, lipidomics, de novo lipogenesis, Group 3 medulloblastoma, Group 4 medulloblastoma, MYC, metabolic reprogramming